SCHEMBL29797058

SCHEMBL29797058

CC(C)(C)OC(=O)N[C@H]1CSc2ccc(-c3nnc(C(C)(C)C)o3)cc2N(Cc2ccc(OC(F)(F)C(F)F)cc2)C1=O

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 5/20 0.39
▸ XIAP P98170 1/20 0.38
▸ NPY1R P25929 1/20 0.35
▸ HDAC6 Q9UBN7 2/20 0.34
▸ RIPK1 Q13546 1/20 0.32
▸ HCRTR1 O43613 1/20 0.32
▸ HCRTR2 O43614 1/20 0.32
▸ F7 P08709 5/20 0.31
▸ F3 P13726 5/20 0.31
▸ F2 P00734 1/20 0.31
▸ S1PR4 O95977 1/20 0.31
▸ S1PR1 P21453 1/20 0.31
▸ S1PR5 Q9H228 1/20 0.31
▸ SCN9A Q15858 2/20 0.31
▸ NPC1 O15118 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26961779 1.00 SRC (0.39) SRCXIAPNPY1RHDAC6RIPK1
SCHEMBL29796984 0.94 SRC (0.38) SRCXIAPNPY1RHDAC6
SCHEMBL26962177 0.94 SRC (0.38) SRCXIAPNPY1RHDAC6
SCHEMBL26962547 0.87 SRC (0.36) SRCXIAPNPY1RHDAC6
SCHEMBL26961640 0.86 NPY1R (0.35) NPY1RHDAC6HCRTR1HCRTR2S1PR4
SCHEMBL26962291 0.85 SRC (0.37) SRCXIAPNPY1RHDAC6SCN9A
SCHEMBL29796785 0.84 SRC (0.34) SRCXIAPNPY1R
SCHEMBL26961653 0.84 SRC (0.34) SRCXIAPNPY1R
SCHEMBL29796857 0.83 SRC (0.36) SRCXIAPNPY1RHCRTR1HCRTR2
SCHEMBL26961825 0.83 SRC (0.36) SRCXIAPNPY1RHCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4291558-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2023-12-20 — — EP disclosed
WO-2022171745-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2022-08-18 — — WO disclosed
Send feedback